PMID- 38323285
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240210
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 14
IP  - 1
DP  - 2024
TI  - A novel immunogenic cell death-related gene risk signature can identify 
      biomarkers of gliomas and predict the immunotherapeutic response.
PG  - 324-343
AB  - Immunogenic cell death (ICD) is a type of cell death that plays a pivotal role in 
      immunity. Recent studies have identified the critical role of ICD in glioma 
      treatment. This study aimed to use ICD-associated differentially expressed genes 
      (ICD-DEGs) to predict survival of glioma patients. We investigated the 
      relationship between clinical prognosis and the date-to-clinical prognosis of 
      1,721 glioma patients by examining the expression, methylation, and mutation 
      status of ICD-related genes (IRGs) in these patients. Our prediction of survival 
      in glioma patients was based on three risk genes, and we explored the association 
      between these genes and clinical outcomes. Additionally, IRG expression was used 
      to stratify glioma patients. We further examined the relationship among the three 
      subgroups in terms of immune microenvironment heterogeneity and immunotherapy 
      response. In addition, this study also included analyses of histograms and 
      sensitivity to antitumor drugs. The expression of these genes was externally 
      validated by RT-qPCR, Western blot (WB), and immunohistochemistry (IHC) in glioma 
      and normal brain tissue. Our findings reveal that most IRGs are overexpressed in 
      glioma tumor tissues, and this high expression was confirmed through histological 
      validation. We successfully developed predictive models for three prognostic 
      genes associated with ICD. These models not only predict survival in glioma but 
      also correlate with the tumor's immune microenvironment. Finally, using consensus 
      clustering, we identified three ICD-associated subtypes. Notably, patients with 
      the C3 subtype showed high levels of immune cell infiltration, whereas those with 
      the C1 subtype exhibited lower levels of immune cell infiltration. We 
      successfully developed an innovative IRG-based systematic approach for evaluating 
      glioma patients. This stratification in experimental studies opens new avenues 
      for prognosis and assessing immunotherapy responses in glioma patients. Our study 
      demonstrates the effectiveness of this approach in treating glioma, potentially 
      paving the way for more promising and effective therapeutic strategies in the 
      future.
CI  - AJCR Copyright (c) 2024.
FAU - Tang, Xuewu
AU  - Tang X
AD  - Longgang District Maternity and Child Healthcare Hospital of Shenzhen City 
      (Longgang Maternity and Child Institute of Shantou University Medical College) 
      Shenzhen, Guangdong, China.
AD  - Department of Hematology and Oncology, Shenzhen Children's Hospital Shenzhen, 
      Guangdong, China.
FAU - Wang, Kan
AU  - Wang K
AD  - Department of Neurosurgery, Harbin Medical University Harbin, Heilongjiang, 
      China.
FAU - Yang, Jinchao
AU  - Yang J
AD  - Longgang District Maternity and Child Healthcare Hospital of Shenzhen City 
      (Longgang Maternity and Child Institute of Shantou University Medical College) 
      Shenzhen, Guangdong, China.
AD  - Department of Hematology and Oncology, Shenzhen Children's Hospital Shenzhen, 
      Guangdong, China.
FAU - Wang, Yuting
AU  - Wang Y
AD  - Department of Hematology and Oncology, Shenzhen Children's Hospital Shenzhen, 
      Guangdong, China.
FAU - Yan, Zhiteng
AU  - Yan Z
AD  - Longgang District Maternity and Child Healthcare Hospital of Shenzhen City 
      (Longgang Maternity and Child Institute of Shantou University Medical College) 
      Shenzhen, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20240115
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10839322
OTO - NOTNLM
OT  - Glioma
OT  - drug sensitivity analysis
OT  - immunogenic cell death (ICD)
OT  - immunotherapy
OT  - tumor microenvironment (TME)
COIS- None.
EDAT- 2024/02/07 06:43
MHDA- 2024/02/07 06:44
PMCR- 2024/01/15
CRDT- 2024/02/07 04:18
PHST- 2023/02/17 00:00 [received]
PHST- 2024/01/01 00:00 [accepted]
PHST- 2024/02/07 06:44 [medline]
PHST- 2024/02/07 06:43 [pubmed]
PHST- 2024/02/07 04:18 [entrez]
PHST- 2024/01/15 00:00 [pmc-release]
AID - 10.62347/VCFG8784 [doi]
PST - epublish
SO  - Am J Cancer Res. 2024 Jan 15;14(1):324-343. doi: 10.62347/VCFG8784. eCollection 
      2024.